The non-coding oncogene: a case of missing DNA evidence?

Puja Shahrouki and Erik Larsson*

Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

INTRODUCTION

Already in the late nineteenth century, more than a decade before the term "gene" was coined, it was suggested that somatic chromosomal alterations could form the basis of tumorigenesis (Von Hansemann, 1890). Proof had to wait until after the birth of modern cytogenetics, when the first reported recurrent genomic aberration in cancer, the famous (9;22) Philadelphia chromosome translocation, was described in the 1960s (Nowell and Hungerford, 1961). With more than half a century's worth of research since that milestone, great advances into understanding the complex genetic nature of cancer have been made (Hanahan and Weinberg, 2011). It is now firmly established that tumor development depends on genomic instability, acquired genetic variability, and microevolutionary selection (Nowell, 1976). From the discovery of the first somatic mutation of a proto-oncogene in 1982 (Reddy et al., 1982; Tabin et al., 1982) to today, hundreds of genes that are somatically mutated or otherwise genomically altered (amplification, deletion, translocation, or epigenetic modification) have been identified and classified as cancer genes (Futreal et al., 2004). Historically, the main focus has been on coding genes and their protein products, and only recently have non-coding RNAs (ncRNAs) started to gain attention as contributors to the development of cancer.

The classic perception of the genome as mainly a substrate for transcription of protein-coding genes has been significantly revised during recent years. High-throughput RNA profiling has revealed that the genome is pervasively transcribed, and that the number of non-coding genes rivals that of coding genes (Figure 1; Kapranov et al., 2002; Harrow et al., 2006; Birney et al., 2007). The discovery of microRNAs has greatly increased the appreciation for ncRNA beyond classical RNA genes, such as ribosomal and transfer RNAs. In addition to small ncRNAs such as microRNAs, transcriptomic studies have revealed an abundance of long ncRNAs (IncRNAs) that lie interspersed with coding genes in complex ways (Carninci et al., 2005; Katayama et al., 2005; Guttman et al., 2010). These constitute a substantial fraction of all human genes (Figure 1), and greatly complicate our view of the mammalian transcriptome.

As awareness grows that ncRNAs participate in important cellular processes, it is also natural to ask whether alterations in ncRNA activities contribute to tumor development. Cancer is a disease of the genome, and ncRNAs should in principle be susceptible to activation, deactivation, and functional modification through introduction of the same types of somatic genomic aberrations that are known to affect coding cancer genes. The completion of the HUGO project (International Human Genome Sequencing Consortium, 2004), and the advent of high-throughput methods for molecular profiling (e.g., microarrays and next-generation sequencing instruments), has greatly facilitated the study of ncRNAs in cancer. However, despite well over 2000 articles relating to microRNAs in cancer being published in 2011 alone (source: PubMed), evidence of specific somatic alteration at the level of DNA still remains relatively sparse. It is also worth noting that many of the techniques used in the pre-genomic era for finding oncogenes and tumor suppressors, such as cell transformation using tumor DNA fragments followed by molecular cloning, or the study of transforming retroviruses (Weinberg, 1982;
MicroRNAs are small, ∼22 nucleotides long, regulatory ncRNAs that modulate gene expression by inhibitory interactions with mRNAs. They are important for a range of biological processes (Bartel, 2009), including proper development of the mammalian embryo (Bernstein et al., 2003). MicroRNAs have been the subject of intense study during the past decade, and are now showing promise as therapeutic targets and biomarkers in cancer and beyond (Rosenfeld et al., 2008; Saunders and Lim, 2009). Numerous studies have revealed frequent differential expression of microRNAs in tumors compared to normal tissues, or between clinical subtypes (Lu et al., 2005; Volinia et al., 2006). Although the overall extent to which these expression changes contribute to tumorigenesis is not clear, convincing experimental and clinical data linking dysregulation of specific microRNAs to tumorigenesis is available in several cases (recently reviewed in Lujambio and Lowe, 2012).

Likewise, genomic copy-number alterations (CNAs) in human cancers have in some cases been linked to microRNA genes, but separating non-functional passenger events from causal changes remains a challenge. One often-cited early example, based on comparative genomic hybridization array data from 227 tumors (breast, ovarian, and melanoma), showed that a high proportion of human microRNAs are located in regions of frequent CNA in cancer (Zhang et al., 2006). However, while this may partially explain why microRNAs are often deregulated in cancer, it does not necessarily implicate microRNAs in tumorigenesis. MicroRNAs are widespread across the genome and large CNAs are frequent in these tumors, and many of the alterations are therefore likely not specifically related to microRNAs. This can be exemplified by the mir-15a/mir-16-1 cluster, encoded by the DLEU2 lncRNA on chromosome 13q14, which in this study was found to be deleted in nearly 25% of both ovarian and breast cancer tumors. However, the 13q14 region harbors numerous other genes, including the RB1 tumor suppressor, which is inactivated in many cancers including ovarian carcinoma (Cancer Genome Atlas Research Network, 2011). The contribution of mir-15a/mir-16-1 is therefore not immediately obvious, and focality/size of aberrations, and/or additional functional data, needs to be taken into account to reliably pinpoint causal ncRNA genes.

In the case of mir-15a/mir-16-1, convincing data in support of a tumor suppressor role comes from chronic lymphocytic leukemia (CLL). In one of the pioneering studies that was able to link somatic alteration of microRNAs to cancer, it was shown that the 13q14 deletion, although already known to be frequent in CLL, was often restricted to a smaller 30 kb region encompassing these microRNAs (Calin et al., 2002). Later studies showed that mir-15a/mir-16-1 are proapoptotic (Cimmino et al., 2005) and, importantly, that deletion of these microRNAs in mice leads to CLL predisposition (Klein et al., 2010). However, in ovarian cancer it should be noted that RB1, but not the nearby DLEU2/mir-15a/mir-16-1, shows a clear pattern of focal deletion (Cancer Genome Atlas Research Network, 2011), suggesting that reported mir-15a/mir-16-1 deletions in ovarian cancer (Zhang et al., 2006) could be passenger events. This example illustrates the difficulties involved in associating genomic aberrations with causal genes, even in the presence of convincing experimental data from other cancer types.

Some of the earliest evidence that microRNAs can have oncogenic properties come from studies of the mir-17-92 cluster on chromosome 13q31, a region known to be amplified in several cancers including diffuse large B-cell lymphoma (DLBCL; Rao et al., 2004). Although microRNAs in this cluster have been implicated as oncogenes in some cases (see below), the mechanism of amplification and its clinical significance are still under investigation.

**SOMATIC GENOMIC ALTERATION OF MICRORNAs IN CANCER**

MicroRNAs are widespread across the genome and large CNAs are frequent in these tumors, and many of the alterations are therefore likely not specifically related to microRNAs. This can be exemplified by the mir-15a/mir-16-1 cluster, encoded by the DLEU2 lncRNA on chromosome 13q14, which in this study was found to be deleted in nearly 25% of both ovarian and breast cancer tumors. However, the 13q14 region harbors numerous other genes, including the RB1 tumor suppressor, which is inactivated in many cancers including ovarian carcinoma (Cancer Genome Atlas Research Network, 2011). The contribution of mir-15a/mir-16-1 is therefore not immediately obvious, and focality/size of aberrations, and/or additional functional data, needs to be taken into account to reliably pinpoint causal ncRNA genes.

In the case of mir-15a/mir-16-1, convincing data in support of a tumor suppressor role comes from chronic lymphocytic leukemia (CLL). In one of the pioneering studies that was able to link somatic alteration of microRNAs to cancer, it was shown that the 13q14 deletion, although already known to be frequent in CLL, was often restricted to a smaller 30 kb region encompassing these microRNAs (Calin et al., 2002). Later studies showed that mir-15a/mir-16-1 are proapoptotic (Cimmino et al., 2005) and, importantly, that deletion of these microRNAs in mice leads to CLL predisposition (Klein et al., 2010). However, in ovarian cancer it should be noted that RB1, but not the nearby DLEU2/mir-15a/mir-16-1, shows a clear pattern of focal deletion (Cancer Genome Atlas Research Network, 2011), suggesting that reported mir-15a/mir-16-1 deletions in ovarian cancer (Zhang et al., 2006) could be passenger events. This example illustrates the difficulties involved in associating genomic aberrations with causal genes, even in the presence of convincing experimental data from other cancer types.

Some of the earliest evidence that microRNAs can have oncogenic properties come from studies of the mir-17-92 cluster on chromosome 13q31, a region known to be amplified in several cancers including diffuse large B-cell lymphoma (DLBCL; Rao et al., 2004). Although microRNAs in this cluster have been implicated as oncogenes in some cases (see below), the mechanism of amplification and its clinical significance are still under investigation.

**FIGURE 1 | Relative abundances of major human gene categories.** The figure is based on the GENCODE (Harrow et al., 2006) annotation (version 11), and numbers refer to gene counts rather than transcripts. Note that additional transcribed loci have been described in other high-throughput gene annotation efforts. Coding genes and lncRNAs were defined as described previously (Jeggari et al., 2012). Pseudogenes here refer to the GENCODE “pseudogene” and “polymorphic pseudogene” categories, and do not include ncRNA pseudogenes. “Misc. RNA” mainly comprises Y RNAs and 7SK RNAs.
Table 1 | NcRNAs specifically targeted by somatic genomic alterations in cancer.

| Name         | Class              | Locus   | Somatic alteration | Function              | Cancer type    | Reference                  |
|--------------|--------------------|---------|--------------------|-----------------------|----------------|----------------------------|
| miR15a/miR-16-1 | microRNA cluster   | 13q14   | Deletion           | Tumor suppressive      | CLL            | Calin et al. (2002)        |
| miR-17-92     | microRNA cluster   | 13q31   | Amplification      | Oncogenic             | Lymphoma       | Ota et al. (2004)          |
| LOC285194 and BC040587 | IncRNA         | 3q13    | Deletion           | Tumor suppressive      | Osteosarcoma   | Plaic et al. (2010)        |
| NC25         | IncRNA             | 6q13    | Mutation           | Tumor suppressive      | Endometrial    | Perez et al. (2008)        |
| GAS5         | IncRNA/snoRNA      | 11q25   | Gene fusion        | Unknown                | B-cell lymphoma | Nakamura et al. (2008)     |
| PTENP1       | Pseudogene/lncRNA  | 9p13    | Deletion           | Tumor suppressive      | Colon          | Poliseno et al. (2010)     |
| SNORA42      | snoRNA             | 1q22    | Amplification      | Oncogenic             | Lung           | Mei et al. (2012)          |
| U50          | snoRNA             | 6q14    | Mutation           | Tumor suppressive      | Prostate, breast | Dong et al. (2008, 2009)   |

Although 13q31 also contains other genes, the miR-17-92 precursor was shown to be the only one at the focal center where expression correlated with copy-number amplitude in DLBCL (Ota et al., 2004). Based on a mouse model of B-cell lymphoma, it was later shown that forced expression of miR-17-92 accelerates tumor development through cooperation with c-Myc (He et al., 2005). MiR-19 was eventually pinpointed as the main oncogenic target in the phosphatidylinositol-3-OH kinase pathway (Olive et al., 2009; Mavragis et al., 2010). Similarly, miR-155 is proximal to B-cell malignancy when overexpressed in mouse B-cells (Costinean et al., 2006) while also frequently being highly expressed in human lymphomas (Eis et al., 2005), although it is unclear whether this primarily happens through transcriptional activation or genomic amplification.

Several other studies have linked CNA in cancer to microRNA genes, albeit at different levels of confidence in terms of functional significance. In one case, 16 microRNA genes were found to show strong support for the idea that altered ncRNA function is important for tumorigenesis. For example, in microsatellite instable gastric and colorectal cancers, recent frame-shift mutations were found in AGO2 and TNRC6A (Kim et al., 2010). Likewise, recurrent somatic mutations (among other, a missense mutation) were identified in the RNase IIB domain of DICER1, in 30/102 non-epithelial ovarian tumors (Heravi-Moussavi et al., 2012). Although these mutations are not targeted at specific microRNAs, they provide strong support for the idea that altered ncRNA function is important for tumorigenesis.

### GENOMIC ALTERATION OF IncRNAs: A LONG STORY MADE SHORT

Long non-coding RNAs are broadly defined as long (arbitrarily >200 nt) transcripts that lack protein-coding capacity but otherwise often have mRNA-like properties, including multi-exonic gene structures and poly(A) tails. Studies point to diverse molecular roles, including recruitment of histone-modifying complexes to chromatin (e.g., XIST, HOTAIR; Plath et al., 2003; Rinn et al., 2007) and regulation of transcription and splicing through interactions with relevant factors (Bernard et al., 2010; Kino et al., 2010). Although early examples were described more than 20 years ago, more recent studies have revealed that mammalian genomes encode thousands of IncRNAs that are often developmentally regulated, and show weak but significant patterns of evolutionarily conservation (Ponjavic et al., 2007; Guttmann et al., 2009). Their biological importance has been debated, but novel IncRNAs are now being characterized at increasing frequency, and these have been shown to have essential roles, e.g., in vertebrate development (Ulitisky et al., 2011), pluripotency (Guttmann et al., 2011), and genome stability (Huarte et al., 2010).
Several studies hint at important roles in oncogenesis for IncRNAs. For example, *HOTAIR* expression is high in breast cancer tumors that are predisposed to metastasize, and its inhibition blocks metastasis in mouse models (Gupta et al., 2010), and *MALAT1* expression correlates with metastases and survival in lung cancer (Ji et al., 2003). Numerous other IncRNAs are altered in cancer at the level of gene expression (recently reviewed in Prensner and Chinnaiyan, 2011), but our knowledge is still limited when it comes to targeted genomic alterations. One recent investigation showed that two IncRNA genes on chromosome 3q13.31, *LOC285194* and *BC040587*, were frequently deleted in osteosarcoma (Pasic et al., 2010). Notably, the deletions were often highly focal, but sometimes also included the nearby protein-coding tumor suppressor *LSAMP*. The results suggest that the genes in this region, which are also coexpressed, may function as a unit. Furthermore, deletion of either IncRNA was associated with poor survival (Pasic et al., 2010). Focal deletion has also been observed in the case of a *PTEN* pseudogene, *PTENPI*, in colon cancer, which can regulate its tumor suppressive coding counterpart by competitive binding to common microRNAs (Poliseno et al., 2010). This intriguing mechanism has been further explored in cancer (Sumazin et al., 2011), and is supported by the observation that microRNAs with many targets tend to have a diluted effect on each individual target (Arvey et al., 2010). Further computational studies are needed to determine whether interactions between microRNAs and other ncRNAs are widespread and conserved (Jeggari et al., 2012).

A few studies suggest that somatic mutations in IncRNAs may be important in cancer, but this remains poorly explored. In one case, a set of 15 highly expressed and conserved IncRNAs were screened for mutations in both cancer cell lines and unmatched normal controls (Perez et al., 2008). Three IncRNAs showed consistent alterations at specific nucleotide positions in at least two cancer cell lines, although it could not be excluded that these represented rare polymorphisms. The mutations were not recapitulated in a panel of 48 matched endometrial tumors and normals, but another IncRNA, NC25, here displayed a striking pattern of somatic alteration, with mutations being present in almost half (23/48) of the patients at one of four distinct positions (Perez et al., 2008). Mutations have also been described in the 3'–end of *MALAT1* (Xu et al., 2011), a IncRNA known to be highly expressed in metastases originating from different cancers (Ji et al., 2003; Ying et al., 2012). It was also determined that the 3'–end of *MALAT1* confers the main biological activity, but the putative functional impact of the actual mutations was never evaluated (Xu et al., 2011).

Ultraconserved regions (UCRs) are genomic elements of near-perfect evolutionary conservation in multiple mammalian genomes, some of which overlap with transcribed regions (exonic, partly exonic, or intronic; Bejerano et al., 2004; Sandelin et al., 2004). UCRs are often located in cancer-associated genomic regions, and several UCRs are transcribed into non-coding transcripts (T-UCRs) whose expression is altered in cancer and is correlated with clinical subtypes and cancer-relevant cellular processes (Calin et al., 2007; Mestdagh et al., 2010). Both somatic and germline mutations have been identified in T-UCRs in colorectal cancer and CLL (Wojcik et al., 2010), but further study is needed to firmly establish if T-UCRs are specific targets of mutation in cancer, or confer heritable risk.

Long non-coding RNA have also been reported to participate in somatic gene fusions. The *GAS5* IncRNA gene, which also harbors several intronic small nuclear RNAs (snORNs), has been found to fuse with the *BCL6* proto-oncogene in a patient with B-cell lymphoma (Nakamura et al., 2008). Similarly, an *ETV1* translocation to an androgen-regulated IncRNA, *PCAT-14*, has been reported in prostate cancer (Prensner and Chinnaiyan, 2011; Prensner et al., 2011). Most likely, IncRNA genes in these cases only contribute regulatory DNA to drive aberrant protein expression, and whether oncogenic IncRNAs themselves can be activated or functionally modulated through genomic translocation remains to be determined.

**SnoRNAs in Tumorigenesis**

Small nucleolar RNAs constitute a well-characterized class of structural RNAs of 60–300 nucleotides in length, with roles in chemical modification of ribosomal RNAs. Emerging evidence suggests that snoRNAs may have specific roles in oncogenesis (reviewed in Williams and Farzaneh, 2012). As an example, tumor-enriched snoRNAs have been identified in lung cancer, and these are detectable in blood plasma at elevated levels in patients compared with healthy controls (Liao et al., 2010). Recent work also suggests that snoRNAs may be specific targets of somatic genomic alteration. In a study based on 10 lung cancer cell lines, it was shown that *SNORA42*, but not its protein-coding host gene, exhibits a high degree of correlation between RNA level and genomic copy-number (Mei et al., 2012). Together with functional data from loss- and gain-of-function experiments in cell lines and mouse xenograft models, this implicates an oncogenic role for *SNORA42*. However, it should also be noted that several other genes in the same genomic region (1q22) display a similar relationship between copy-number and RNA level (Li et al., 2006).

In addition to *SNORA42*, the snoRNA *U50* has been implicated in prostate and breast cancer, where it is commonly deleted together with other genes in the 6q14-22 region (Dong et al., 2008, 2009). Interestingly, identical 2-bp somatic deletions in *U50* were discovered in 9/89 of prostate and 4/49 breast tumors studied, and germline homozygosity for the same deletion was associated with prostate cancer in a larger case-control study (Dong et al., 2008, 2009). Collectively, these studies are intriguing and point to specific roles for snoRNAs in cancer, beyond housekeeping functions related to protein synthesis.

**Concluding Remarks and Perspectives**

Here, we have attempted to summarize current evidence for specific somatic alteration of ncRNAs in cancer (Table 1). Though only briefly discussed here, germ line mutations are also of paramount importance: in addition to potential benefits for early cancer diagnostics, associations between natural genetic variants, or familial mutations, and cancer susceptibility can pinpoint important cancer ncRNAs. In addition, only when considering both genetic and epigenetic aspects will the picture be complete.

It is already clear that altered ncRNA function, by genomic change or other means, is of importance in tumorigenesis. However, due to the rapid evolution of high-throughput genomics, the
detailed map of ncRNA alterations in cancer is likely to change sig-
nificantly in the near future. In particular, resequencing in cancer is
transitioning from whole-exome to whole-genome (Meyerson et al., 2010),
effectively putting more emphasis on non-coding se-
quences. This technique is not without challenges, including the
separation of low-frequency functional alterations from numer-
ous non-contributing ones (Boehm and Hahn, 2011). However,
increasingly comprehensive patient cohorts will eventually help
reveal whether specific somatic alteration of ncRNAs is com-
monplace in cancer. In addition to improving our understanding of
tumor development, these studies hold the exciting promise
of pinpointing important novel ncRNAs that are crucial to the
physiology of the normal mammalian cell.

ACKNOWLEDGMENTS

The authors wish to thank Drs. Anders Jacobsen and Nicholas
Gauthier for critical review of the manuscript. Erik Larsson
was supported by the Swedish Medical Research Council; the
Assar Gabrielsson Foundation; the Magnus Bergvall Foundation;
and the Lars Hierta Memorial Foundation. Puja Shahrouki
was supported by a scholarship from the Erik and Lily Philipsson
Foundation.

REFERENCES

Arvey, A., Larsson, E., Sander, C., Leslie, C. S., and Marks, D. S. (2010).
Target miRNA abundance dilutes microRNA and siRNA activity. Mol.
Syst. Biol. 6, 363.
Angello, C., Vaira, V., Caruso, L., Destro, A., Maggioni, M., Park, Y. N.,
Montorsi, M., Santambrogio, R., Roncalli, M., and Bosari, S. (2012).
MicroRNA profiling of hepatocarcinogenesis identifies C19MC clus-
ter as a novel prognostic biomarker in hepatocellular carcinoma.
Liver Int. 32, 772–782.
Barzel, D. P. (2009). MicroRNAs: tar-
target recognition and regulatory func-
tions. Cell 136, 215–233.
Bejerano, G., Phaestas, M., Makunin, I., Stephen, S., Kent, W. J., Mattick,
J. S., and Hausler, D. (2004). Ultrasondered elements in the
human genome. Science 304, 1321–1325.
Bernard, D., Prasanth, K. V., Colasse, S., Nakamura, T., Xuan, W.,
Choo, C. Y., Ucla, C., Manzano, W., Ooi, H. S., Chiu, K. P.,
Foisier, A., Moqtaderi, Z., Zhi, Z., Xu, X., Squazzo, S., Oberley, M. J.,
Inman, D., Singer, M. A., Richmond, T. A., Munn, K. J., Rada-Iglesias,
A., Wellerman, O., Komorowski, J., Fowler, J. C., Couttet, P., Bruce,
A. W., Dovey, O. M., Ellis, P. D., Lang,
ford, C. F., Nix, D. A., Euskirchen, G., Hartman, S., Urban, E. A., Kraus,
P., Van Calcar, S., Heintzman, N., Kim, T. H., Wang, K., Vu, C., Hon,
G., Luna, R., Glass, C. K., Rosen-
feld, M. G., Aldred, S. F., Cooper, S. J., Hales, A., Lin, J. M., Shulha,
H. P., Zhang, X., Xu, M., Haidar, J. N., Yu, Y., Ruan, Y., Iyer, V. R.,
Green, R. D., Wadelius, C., Farn-
ahm, P. J., Ren, B., Harte, R. A., Hin-
richs, A. S., Trumbower, H., Claw-
son, H., Hillman-Jackson, J., Zweig,
A. S., Smith, K., Thakkapallayil, A.,
Barber, G., Kuhn, R. M., Karolchik,
D., Armengol, L., Bird, C. P., of
Bakker, P. I., Kern, A. D., Lopez-
Bigas, N., Martin, J. D., Stranger,
B. E., Woodroofe, A., Davydov, E.,
Dimas, A., Eyras, E., Hallgrimsdottir,
I. B., Huppert, I., Zody, M. C., Abeca-
sis, G. R., Estivill, X., Bouffard, G. G.,
Guan, X., Hansen, N. F., Idol, J. R.,
Maduro, V. Y., Maskeri, B., McDow-
ell, J. C., Park, M., Thomas, P. J.,
Young, A. C., Blakesley, R. W., Muzny,
D. M., Sodergren, E., Wheeler, D.
A., Worley, K. C., Jiang, H., Wein-
stock, G. M., Gibbs, R. A., Graves, T.,
Fulton, R., Mardis, E. R., Wilson, R.
K., Clamp, M., Guff, J., Gnerre, S.,
Jaffe, D. B., Chang, J. L., Lindblad-
Toh, K., Lander, E. S., Korabine, M.,
Nefedov, M., Osoegawa, K., Yosh-
naga, Y., Zhu, B., and de Jong, P. J. (2007). Identification and analy-
sis of functional elements in 1% of the human genome by the ENCODE
project. Nature 447, 799–816.
Boehm, J. S., and Hahn, W. C. (2011).
Towards systematic functional char-
acterization of cancer genomes. Nat.
Rev. Genet. 12, 487–498.
Calin, G. A., Dumitriu, C. D., Shimizu,
M., Bichi, R., Zupo, S., Noch, D.,
Alder, H., Rattan, S., Keating, M.,
Rai, K., Rassenti, L., Kipps, T.,
Negrini, M., Bulkth, F., and Croce,
C. M. (2002). Frequent deletions and
down-regulation of micro-RNA genes miR15 and miR16 at 13q14
in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99,
15524–15529.
Calin, G. A., Ferracin, M., Cimmino,
A., Di Leva, G., Shimizu, M., Wij-
cick, S. E., Iorio, M. V., Visone, R.,
Sever, N. L., Fabbri, M., Iorio, R.,
Palmbo, T., Pichiorri, F., Baldé, C.,
Garzon, R., Sevignani, C., Rassenti,
L., Alder, H., Volinia, S., Liu, C. G.,
Kipps, T. J., Negrini, M., and Croce,
C. M. (2005). A microRNA signature associated with progression and
progression in chronic lympho-
ctic leukemia. N. Engl. J. Med. 353,
1793–1801.
Calin, G. A., Li, C. G., Ferracin, M.,
Hyslop, T., Spizzo, R., Sevignani, C.,
Fabbri, M., Cimmino, A., Lee, E. I.,
Wojcik, S. E., Shimizu, M., Tili, E.,
Rossi, S., Taccioli, C., Pichiorri, F.,
Liu, X., Zupo, S., Herlea, V., Gra-
mantieri, L., Lanza, G., Alder, H.,
Rassenti, L., Volinia, S., Schmittgen,
T. D., Kipps, T. J., Negrini, M., and
Croce, C. M. (2007). Ultrasondered regions encoding ncRNAs are altered
in human leukemias and carcino-
as. Cancer Cell 12, 215–229.
Cancer Genome Atlas Research Net-
work. (2011). Integrated genomic
analyses of ovarian carcinoma.
Nature 474, 609–615.

www.frontiersin.org
Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M. C., Maeda, N., Ozawa, R., Rice, W. E., Watanabe, N., Watanabe, T., Yamanishi, Y., Kasukawa, T., HPD Consortium, I., Furuno, M., Futahara, K., Tanabe, Y., Washiyama, T., Fujibayashi, S., Furuno, R., Kasukawa, A., Gough, C., Frith, M. C., Veryazov, S., Gotoh, O., Human Protein Reference Database (HPRD), I., and Human Protein Reference Database, I. (2005). The human protein reference database in 2005: expanding and updating the functional annotation of 30 000 human genes. Nucleic Acids Research 33, D417–D420.

Du, P. S., Siebert, M., Hettich, P., Biggins, J., and Chang, H. Y. (2010). Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071–1076.

Guttman, M., Amit, I., Garber, M., French, C., Lin, M., Felder, D., Huarte, M., Zuk, O., Carey, B. W., Cassidy, J. P., Cabili, M. N., Jaenisch, R., Mikkelson, T. S., Jacks, T., Hacohen, N., Bernstein, B. E., Kellis, M., Regev, A., Rinn, J. L., and Enderling, E. S. (2009). Chromatin signature reveals over a thousand highly conserved non-coding RNAs in mammals. Nature 458, 223–227.

Guttman, M., Donaghey, J., Carey, B. W., Garber, M., Grenier, J. K., Munson, G., Young, G., Lucas, A. B., Ach, R., Brunn, L., Yang, X., Amit, I., Meissner, A., Regev, A., Rinn, J. L., Root, D. E., and Enderling, E. S. (2011). lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477, 299–306.

Guttman, M., Garber, M., Levin, J. Z., Donaghey, J., Robinson, J., Adiconis, X., Fan, L., Kozol, M. J., Grinke, A., Nusbaum, C., Rinn, J. L., Lang, E. S., and Regev, A. (2010). Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat. Biotechnol. 28, 503–510.

Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–674.

Harlow, D., Menoeud, F., Frankish, A., Reymond, A., Chen, C. K., Chrast, J., Lagarde, J., Gilbert, J. G., Storey, J. W., Swarbreck, D., Rossier, C., Udall, J., Hubbard, T., Antonarakis, S. E., and Guigo, R. (2006). GENCODE: producing a reference annotation for ENCODE. Genome Biol. 7(Suppl. 1), S4–1.

He, L., Thomson, J. M., Hemann, M. T., Hernandez-Monge, E. G., Dittrich-Burks, S., Goodwin, S., Powers, S., Corden, M., Cardo, C., Lowe, S. W., Hannon, G. J., and Korbel, J. O. (2010). A human microRNA catalogue and its relationship to disease. Nature 468, 827–833.

Heravi-Moussavi, A., Anglesio, M. S., and Croce, C. M. (2006). Pre-B cell leukemia/lymphoma 1 (Prb1l), a novel gene at 6q14.3 with a mutation in E(mu)-miR155 transgenic mice. Hum. Mol. Genet. 15, 6097–6104.

Hori, J., and Kato, R. (2010). The significance of 3′ untranslated region expanse in cell type-specific transcriptomes in mouse. Cancer Sci. 101, 1031–1042.

Ito, S. P., Tam, W., Sun, L., Chad burn, A. L., Zito, M. F., Lund, E., and Dahlberg, J. E. (2005). Accumulation of miR-155 and BIC microRNA polycistron as a potent regulator of cell growth. Proc. Natl. Acad. Sci. U.S.A. 102, 19344–19349.

Jakt, M., Kanapin, A., Katoh, M., Kawashita, T., Kawai, J., Suzuki, H., Carninci, P., Kozol, M. J., Nishida, H., Yapi, C. C., Suzuki, H., Hayashizaki, Y., FANTOM Consortium, I., and Genome Research Group and Genome Reference Group, RIKEN Genome Exploration Research Program Core Group. (2005). The mammalian genome. Nature Rev. Cancer 5, 7024–7029.

Kapranov, P., Cawley, S. E., Dekov, J., Bekiranov, S., Abraldes, G., Fodor, S. P., and Gingeras, T. R. (2002). Large-scale transcriptional activity in chromosomes 21 and 22. Science 296, 916–919.

Katayama, S., Tomaru, Y., Kasukawa, T., Waki, K., Nakashima, M., Nakamura, M., Nishida, H., Yap, C. P., Suzuki, M. K., Kawai, T., Suzuki, H., Carninci, P., Hayashizaki, Y., Wells, C., Frith, M., Davoli, T., Park, G. C., Dunlop, A., De, S., and Conlon, K. (2010). Somatic deletion of non-coding RNAs in pancreatic cancer. Nature 464, 224–228.

Kim, S. M., Oh, J. E., Kim, Y. R., Park, S. W., Kang, M. R., Kim, S. S., Ahn, C. H., Yoo, N. J., and Lee, S. H. (2010). Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TRCN6 in gastric and colorectal cancers. J. Pathol. 221, 139–146.

Kinho, T., Hurt, D. E., Ichijo, T., Nader, N., and Chrousos, G. P. (2010). Non-coding RNA gas5 is a growth arrest- and starvation-associated repressor
of the glucocorticoid receptor. Sci. Signal. 3, ra21.

Klein, L. J., Liao, M., Crespo, M., Gisler, R., Shen, Q., Mo, T., Ambesi-Impiombato, A., Califano, A., Migli dazzo, G., Bhagat, G., and Dalla Fave ra, R. (2010). The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Carcin Cancer Cell 17, 28–40.

Knudson, A. G. (1993). Antioncogenes and human cancer. Proc. Natl. Acad. Sci. U.S.A. 90, 10914–10921.

Li, R., Wang, H., Bekele, B. N., Yin, Z., Caraway, N. P., Katz, R. L., Stass, S. A., and Ji, F. (2006). Identification of putative oncopgenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene 25, 2628–2635.

Liao, J., Yu, L., Mei, Y., Guarniera, M., Shen, J., Li, R., Liu, Z., and Ji, F. (2010). Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol. Cancer 9, 198.

Lionetti, M., Agnellino, M., Mosca, L., Fab ris, S., Andronache, A., Todoerti, K., Ronchetti, D., Deliliers, G. L., and Neri, A. (2009). Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 48, 521–531.

Liu, A. M., Zhang, C., Burchard, J., Fan, S. T., Wong, K. F., Dai, H., Poon, R. T., and Luk, J. M. (2012). Role of miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28–40.

Liu, A. M., Liao, M., Crespo, M., Gisler, R., Shen, Q., Mo, T., Ambesi-Impiombato, A., Califano, A., Migliazzzo, A., Bhagat, G., and Dalla Favera, R. (2010). The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28–40.
interactions regulates established oncogenic pathways in glioblastoma. Cell 147, 370–381.

Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., and Chang, E. H. (1982). Mechanism of activation of a human oncogene. Nature 300, 143–149.

Ulitsky, I., Shkumatava, A., Jan, C. H., Sive, H., and Bartel, D. P. (2011). Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution. Cell 147, 1537–1550.

Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R. L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris, C. C., and Croce, C. M. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257–2261.

Von Harschmann, D. (1890). Ueber asymmetrische Zelltheilung in Epithelhresbsen und deren biologische bedeutung. Virchows Arch. A Pathol. Anat. 119, 299–326.

Weinberg, R. A. (1982). Fewer and fewer oncogenes. Cell 30, 3–4.

Williams, G. T., and Farzaneh, F. (2012). Are snoRNAs and snoRNA host genes new players in cancer? Nat. Rev. Cancer 12, 84–88.

Wojcik, S. E., Rossi, S., Shimizu, M., Nicoloso, M. S., Cimmino, A., Alder, H., Herlea, V., Rassenti, L. Z., Rai, K. R., Kipps, T. J., Keating, M. J., Croce, C. M., and Calin, G. A. (2010). Non-coding RNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis 31, 208–215.

Xu, C., Yang, M., Tian, J., Wang, X., and Li, Z. (2011). MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int. J. Oncol. 39, 169–175.

Ying, L., Chen, Q., Wang, Y., Zhou, Z., Huang, Y., and Qiu, F. (2012). Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol. Biomol. 8, 2289–2294.

Zhang, L., Huang, J., Yang, N., Greshock, J., Megraw, M. S., Giannakakis, A., Liang, S., Naylor, T. L., Barchetti, A., Ward, M. R., Yao, G., Medina, A., O’Brien-Jenkins, A., Katsaros, D., Hatzigeorgiou, A., Gimotty, P. A., Weber, B. L., and Coukos, G. (2006). microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. U.S.A. 103, 9136–9141.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 27 July 2012; paper pending published: 14 August 2012; accepted: 17 August 2012; published online: 12 September 2012.

Citation: Shahrouki P and Larsson E (2012) The non-coding oncogene: a case of missing DNA evidence? Front. Genet. 3:170. doi: 10.3389/fgene.2012.00170

This article was submitted to Frontiers in Non-Coding RNA, a specialty of Frontiers in Genetics.

Copyright © 2012 Shahrouki and Larsson. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.